Evidence map›Paper›PMID 42500357›Full record

ArticleLancet regional health. Americas2026

Health-care provider compliance with a revised

Elisa Vidal-Cardenas, Catharine I De Freitas-Vidal, Veronica Soto-Calle, Hugo Rodríguez-Ferrucci, Wilma Casanova, Ivan Condori-Lizarraga, Stephan Duparc, Elodie Jambert, Melanie Larson, Heike Huegel and 4 more

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Elisa Vidal-CardenasMMV Medicines for Malaria Venture, Geneva, Switzerland.
Catharine I De Freitas-VidalMMV Medicines for Malaria Venture, Geneva, Switzerland.
Veronica Soto-CalleUnidad de Leishmaniasis y Malaria, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
Hugo Rodríguez-FerrucciUniversidad Nacional de la Amazonía Peruana, Iquitos, Peru.
Wilma CasanovaUniversidad Nacional de la Amazonía Peruana, Iquitos, Peru.
Ivan Condori-LizarragaUnidad de Leishmaniasis y Malaria, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
Stephan DuparcMMV Medicines for Malaria Venture, Geneva, Switzerland.
Elodie JambertMMV Medicines for Malaria Venture, Geneva, Switzerland.
Melanie LarsonMMV Medicines for Malaria Venture, Geneva, Switzerland.
Heike HuegelMMV Medicines for Malaria Venture, Geneva, Switzerland.
Thy DoMMV Medicines for Malaria Venture, Geneva, Switzerland.
Paula Alejandra BurelaMMV Medicines for Malaria Venture, Geneva, Switzerland.
Marcus LacerdaFundação de Medicina Tropical Dr Heitor Vieira Dourado and Fiocruz, Manaus, Brazil.
Alejandro Llanos-CuentasUnidad de Leishmaniasis y Malaria, Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: This prospective, observational study in Loreto, Peru (Aug 2022-Dec 2024) evaluated implementation of a revised radical cure algorithm among patients by trained routine HCPs across 14 health facilities. HCP compliance was assessed from the provider (correct algorithm application in ≥80% of patients per HCP role) and patient perspectives (proportion correctly treated per algorithm). Safety endpoints included acute haemolytic anaemia (AHA) and other serious adverse events. Findings: Among 187 HCPs and 987 patients, HCP compliance was 96.6% (172/178) from the provider perspective and 98.7% (974/987) from the patient perspective, with similar results across urban/periurban and remote/rural facilities. Incorrect treatments (1.3%; 13/987) were mostly due to operational lapses in treatment sequencing and eligibility among G6PD-normal individuals. Ten patients (1.1%; 10/916) developed symptoms suggestive of AHA; one met suspected AHA criteria, unconfirmed. Eight patients (0.8%; 8/986) experienced serious adverse events attributable to severe malaria; all recovered. Interpretation: HCPs across participating facilities achieved high compliance with the revised radical cure algorithm from both perspectives and consistently across urban/periurban and remote/rural settings. Incorrect treatments were infrequent and no AHA was confirmed. These findings demonstrate that HCP at the participating facilities can successfully implement the revised radical cure algorithm, contributing to the operational evidence base informing its scale-up in Peru and the Americas. Funding: Unitaid (Grant number 2021-43-VIV).

Indexed as

ComplianceG6PD testingHealth care providerHealth systemsImplementation scienceLatin AmericaMalariaMalaria eliminationMalaria treatment guidelinesMixed-methods researchOperational researchPeruPlasmodium vivaxPoint-of-care diagnosticsProvider behaviourRadical cureReal-world evidenceTafenoquineTreatment uptake

Identifiers

PMID42500357
PMCPMC13396956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.